Table 1 Patient Demographics and Tumor Characteristics
From: A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Characteristic | No. Patients (%) N = 125 |
|---|---|
Median age, years (range) | 62 (37-84) |
Performance status (ECOG) | |
0-1 | 98 (78) |
2 | 21 (17) |
3 | 3 (2) |
Unknown | 3 (2) |
Hormone receptor status | |
Positive | 75 (60) |
Negative | 37 (30) |
Unknown | 13 (10) |
Active Treatment setting | |
Neoadjuvant | 1 (<1) |
Adjuvant | 1 (<1) |
First-line advanced | 14 (11) |
Second-line advanced | 51 (41) |
Third-line advanced | 35 (28) |
Fourth-line advanced or greater | 23 (18) |
Prior treatments | |
Surgery | 116 (93) |
Hormone therapy | 89 (71) |
Prior anthracycline therapy | 70 (56) |
Palliative chemotherapy | 81 (65) |
Adjuvant chemotherapy | 54 (43) |
Immunotherapy | 8 (6) |
Site of metastasis | N = 123 |
Bone | 69 (56) |
Liver | 56 (4) |
Lung | 44 (36) |
Skin | 14 (11) |
Lymph nodes | 13 (11) |
Pleura | 8 (6) |
Brain | 7 (6) |
Others | 26 (21) |